R399E, A Mutated Form of Growth and Differentiation Factor 5, for Disease Modification of Osteoarthritis.
Gigout, A., Werkmann, D., Menges, S., Brenneis, C., Henson, F., Cowan, K.J., Musil, D., Thudium, C.S., Guhring, H., Michaelis, M., Kleinschmidt-Doerr, K.(2023) Arthritis Rheumatol 75: 375-386
- PubMed: 36054172 
- DOI: https://doi.org/10.1002/art.42343
- Primary Citation of Related Structures:  
7ZJF - PubMed Abstract: 
To preclinically characterize a mutant form of growth and differentiation factor 5, R399E, with reduced osteogenic properties as a potential disease-modifying osteoarthritis (OA) drug.
Organizational Affiliation: 
Merck Healthcare KGaA 64293, Darmstadt, Germany.